A set of evidence-based nomograms for predicting recovery of erectile function after radical prostatectomy is now available, and the developers hope that surgeons will use these tools to provide prostate cancer patients with a more accurate personalized estimate of their sexual function outcome.
Cheryl Guttman Krader
Access to novel therapies early in the regulatory process as a result of the FDA’s accelerated approval program can be valuable for many cancer patients, but the clinicians who are responsible for their care must have heightened vigilance for incoming data and FDA guidance about these drugs that have not gone through the “gold standard” of phase III testing.
Findings from 18-fluciclovine (Axumin) positron emission tomography/computed tomography imaging had a major impact on management decisions for men with biochemical recurrence of prostate cancer.
Published findings from PROCEED, a large registry collecting data from men treated with sipuleucel-T (Provenge) for asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer, provide valuable insight on real-world outcomes associated with this immunotherapy agent in the modern era of prostate cancer management.
Sacral neuromodulation placement in a single-stage procedure is likely to be less costly than a two-stage approach for most practitioners, according to the findings of a cost minimization analysis.
Data from prospective clinical trials show that the efficacy of high-velocity waterjet ablation (Aquablation using the AquaBeam System) for improving BPH-related signs and symptoms is the same in patients with a large-to-very large prostate as in men with a small-to-moderate size gland, said Naeem Bhojani, MD, at the AUA annual meeting in Chicago.
The long-term durability of surgical modalities for management of BPH varies significantly, findings from a retrospective study suggest.
Analyses of data collected in PROCEED, a large real-world registry, corroborate phase III study findings demonstrating that sipuleucel-T (Provenge) treatment for metastatic castrate-resistant prostate cancer has a particular benefit for improving overall survival in African-American men.
Analyses based on number needed to treat benefit show that the overall survival benefit is similar when using abiraterone acetate (ZYTIGA), enzalutamide (XTANDI), or sipuleucel-T (Provenge) to treat men with chemotherapy-naïve metastatic castration-resistant prostate cancer. The data, however, favor sipuleucel-T for having the lowest direct cost.
“The variability in recommendations [for hematuria evaluation] and our study’s findings highlight implicit value judgments and a potentially high burden of harms not historically considered in many guidelines’ development process," says Matthew E. Nielsen, MD, MS.